Dr. Steven Fox, CEO of Akelos Inc., discusses the challenges of developing new non-opioid medical products as the need intensifies as the crisis worsens.
Moe Alsumidaie
Advertisement
Articles by Moe Alsumidaie
The FDA’s Dr. John Whyte offers his perspectives on patient centricity and the issues that FDA and industry are facing.
Amidst arguments that industry is heading for another economic recession, Moe Alsumidaie reminds us that biopharma has shown resiliency during such times.
Moe Alsumidaie looks at data collection methods and concepts that can result in predicting patients at risk of dropping out from a clinical trial.
The report analyzed data from several biopharmaceutical and medical device clinical trials, and emphasized several observations
Advertisement
Latest Updated Articles
- Enhancing Racial Diversity in Clinical Trials
Published: September 18th 2013 | Updated:
- Income and Depression: A Predictive Model for Clinical Trials Patient Dropout
Published: February 22nd 2015 | Updated:
Will Another Recession Bash the Biopharmaceutical Industry?Published: May 3rd 2016 | Updated:
FDA’s John Whyte Delves Deeper into Patient CentricityPublished: November 30th 2016 | Updated:
Emerging Biopharma Tackles the Opioid CrisisPublished: September 12th 2019 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
Johnson and Johnson Reveals Plan to Separate Orthopaedics Business
2
The Most-Favored-Nation Policy: Outlook and Implications Beyond U.S.
3
Nabla Bio Enters $1 Billion Multi-Year Research Collaboration with Takeda
4
The Evolving Landscape in Psychiatry: Challenges and Opportunities for Biopharma
5
